Research Journal / ROYAL PEPTIDES RESEARCH

Retatrutide vs Eloralintide: Triple Agonist vs Amylin Agonist

Retatrutide (LY3437943) targets GIP, GLP-1 and glucagon receptors; Eloralintide (LY3841136) targets amylin receptors. Mechanisms, trial data and status compared.

November 10, 20263 min readResearch Journal

Retatrutide and Eloralintide are both investigational Eli Lilly peptides studied in metabolic research, but they work on completely different hormone systems. Retatrutide (LY3437943) is a triple agonist of the GIP, GLP-1 and glucagon receptors. Eloralintide (LY3841136) is a selective amylin receptor agonist. Neither is approved by the FDA or Health Canada.

Retatrutide vs Eloralintide at a glance

Retatrutide (Reta)Eloralintide (Elora)
Developer codeLY3437943LY3841136
Hormone familyIncretins + glucagonAmylin
Receptors targetedGIP, GLP-1 and glucagon receptorsAmylin receptors (selective)
Key Phase 2 result24.2% average weight reduction at 48 weeks, highest-dose group (NEJM, 2023)Up to 20.1% average weight reduction at 48 weeks, 9 mg group (The Lancet, 2025)
Development stagePhase 3 TRIUMPH programme reported 2025–2026; FDA filing planned Q1 2027Phase 3 ENLIGHTEN programme began enrolling in 2026
Regulatory statusInvestigationalInvestigational

Two different mechanisms

Retatrutide: three receptors at once

Retatrutide is a single 39-amino-acid peptide that activates the GIP, GLP-1 and glucagon receptors. Its 2022 discovery paper reported the strongest potency at GIP and the weakest at glucagon. The glucagon component is studied for its effects on energy expenditure and liver fat, while the incretin components are studied for glucose control and appetite signalling. For identifiers, sequence details and the full trial timeline, see the Retatrutide (Reta) research profile.

Eloralintide: the amylin pathway

Amylin is a hormone released alongside insulin by pancreatic beta cells. It is studied mainly for its role in satiety, slowing of gastric emptying and post-meal glucagon suppression. Eloralintide is designed as a long-acting, selective amylin receptor agonist, so it works through a separate signalling system from GLP-1-based compounds. Lilly’s preclinical work compared it directly with cagrilintide, Novo Nordisk’s amylin analogue. See the Eloralintide research profile for its specifications.

What the clinical data show

The two compounds are at different stages, so their data are not directly comparable.

  • Retatrutide has reported four Phase 3 trials. In TRIUMPH-1 (2,339 adults, 80 weeks), Lilly reported 28.3% average weight reduction in the highest-dose group under the efficacy estimand, or 25.0% counting everyone randomised. TRIUMPH-2 and TRIUMPH-3 reported 20.8% and up to 22.6% in their populations.
  • Eloralintide reported Phase 2 results in November 2025: 263 adults without type 2 diabetes, 48 weeks, with mean reductions from 9.5% (1 mg) to 20.1% (9 mg) against 0.4% on placebo (efficacy estimand). The most common adverse events were gastrointestinal symptoms and fatigue, more frequent at higher doses.

When comparing figures across trials, check the estimand, trial length and population. A 48-week Phase 2 result and an 80-week Phase 3 result answer different questions.

Why researchers study them together

Because they act on different pathways, incretin-based and amylin-based compounds are increasingly studied in combination. Novo Nordisk’s CagriSema pairs semaglutide with cagrilintide. Lilly has reported a Phase 2 study of eloralintide combined with tirzepatide (EloraTZP) in adults with type 2 diabetes, with Phase 3 planned. Whether combining a triple agonist such as retatrutide with an amylin agonist adds anything is an open research question with no published clinical data yet.

Frequently asked questions

Is Retatrutide the same as Eloralintide?

No. Retatrutide activates the GIP, GLP-1 and glucagon receptors. Eloralintide activates amylin receptors. They belong to different hormone families.

Which is further along in development?

Retatrutide. It has reported Phase 3 results, and Lilly plans an FDA filing in early 2027. Eloralintide entered Phase 3 in 2026.

Are Retatrutide or Eloralintide FDA approved?

No. Both are investigational compounds.

What is “Reta”?

“Reta” is an informal short name for Retatrutide (LY3437943).

A note on research use

Royal Peptides supplies research-grade Retatrutide and Eloralintide strictly for in-vitro laboratory research. They are not medicines and are not for human or veterinary use. The clinical results above come from published trials of investigational drugs and do not describe research-grade material. Batch certificates of analysis are published in the COA library.

References

  1. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022;34(9):1234–1247. PubMed
  2. Jastreboff AM, et al. Triple–hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. N Engl J Med. 2023;389:514–526. NEJM
  3. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 trial. The Lancet, 2025. PubMed
  4. Eli Lilly. Eloralintide Phase 2 results, 6 November 2025. Lilly
  5. Eli Lilly. Retatrutide TRIUMPH-1 Phase 3 results, 21 May 2026. Lilly
ROYAL PEPTIDES · RESEARCH & INSIGHTS